By now we’ve recognized the survival advantage of prostate-directed radiation in the setting of oligometastatic disease, but at what cost? Not financial, we’ve already visited that. This quality of life secondary analysis of the HORRAD trial demonstrates, to no surprise, that adding radiation to ADT adds acute bowel and bladder symptoms. While bladder issues resolve by 6 months, 1 in 5 men still had bowel symptoms at 2 years. | Boevé, Euro Urol 2020


Popular Posts